PE20071042A1 - Producto farmaceutico que comprende temsirolimus y malato de sunitinib - Google Patents
Producto farmaceutico que comprende temsirolimus y malato de sunitinibInfo
- Publication number
- PE20071042A1 PE20071042A1 PE2006001343A PE2006001343A PE20071042A1 PE 20071042 A1 PE20071042 A1 PE 20071042A1 PE 2006001343 A PE2006001343 A PE 2006001343A PE 2006001343 A PE2006001343 A PE 2006001343A PE 20071042 A1 PE20071042 A1 PE 20071042A1
- Authority
- PE
- Peru
- Prior art keywords
- sunitinib malate
- temsirolimus
- pharmaceutical product
- product including
- inhibitor
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 title abstract 2
- 229960002812 sunitinib malate Drugs 0.000 title abstract 2
- 229960000235 temsirolimus Drugs 0.000 title abstract 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 239000002295 alkylating antineoplastic agent Substances 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229960004630 chlorambucil Drugs 0.000 abstract 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124303 multikinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA ENZIMA BLANCO DE RAPAMICINA EN MAMIFEROS (mTOR) QUE ES TEMSIROLIMUS; Y B) MALATO DE SUNITINIB, ADMINISTRADOS EN UNA CANTIDAD SUBTERAPEUTICAMENTE EFECTIVA. DONDE LA COMBINACION COMPRENDE ADEMAS OTRO COMPONENTE ACTIVO SELECCIONADO DE AGENTES ALQUILANTES ANTINEOPLASICOS TAL COMO CICLOFOSFAMIDA, CLORAMBUCIL, CISPLATINO, ENTRE OTROS; AGENTES ANTIMETABOLITO ANTINEOPLASICOS TAL COMO CITARABINA, METOTREXATO, GEMCITABINA, ENTRE OTROS; INMUNOMODULADORES BIOQUIMICOS TAL COMO LEUCOVORINA O LEVOFOLINATO; IMATINIB; INHIBIDORES DE EGFR, INHIBIDOR MULTIQUINASA O UN INTERFERON. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE CARCINOMA DE CELULAS RENALES, CANCER DE MAMA, CANCER DE COLON, LEUCEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73356405P | 2005-11-04 | 2005-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071042A1 true PE20071042A1 (es) | 2007-10-12 |
Family
ID=37882361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001343A PE20071042A1 (es) | 2005-11-04 | 2006-11-02 | Producto farmaceutico que comprende temsirolimus y malato de sunitinib |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070105887A1 (es) |
| AR (1) | AR058505A1 (es) |
| PE (1) | PE20071042A1 (es) |
| TW (1) | TW200803842A (es) |
| WO (1) | WO2007056117A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| WO2007059106A2 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of mntor inhibitor to treat patients with cancer |
| DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| JP2010509400A (ja) | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
| CA2676168A1 (en) * | 2007-01-30 | 2008-08-07 | Schering Corporation | Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| WO2009065232A1 (en) * | 2007-11-20 | 2009-05-28 | University Health Network | Cancer diagnostic and therapeutic methods that target plk4/sak |
| BRPI0914790A2 (pt) | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX2013003599A (es) * | 2010-10-01 | 2013-07-29 | Biogen Idec Inc | Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer. |
| WO2013116781A1 (en) | 2012-02-02 | 2013-08-08 | Acceleron Pharma Inc. | Alk1 antagonists and their uses in treating renal cell carcinoma |
| CA2866021C (en) * | 2012-03-06 | 2020-09-22 | The Board Of Trustees Of The University Of Illinois | Procaspace 3 activation by pac-1 combination therapy |
| US9931313B2 (en) * | 2012-04-04 | 2018-04-03 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス，インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
| KR20170068597A (ko) | 2014-10-27 | 2017-06-19 | 텐샤 세러퓨틱스 인코포레이티드 | 브로모도메인 저해제 |
| CN105434435B (zh) * | 2015-12-07 | 2018-07-17 | 西安交通大学 | 一种具有协同抗肿瘤功效的药物组合物及其应用 |
| SG11202005719UA (en) * | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| WO2005049021A1 (en) * | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
| AU2006245421A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
-
2006
- 2006-11-02 US US11/591,979 patent/US20070105887A1/en not_active Abandoned
- 2006-11-02 TW TW095140555A patent/TW200803842A/zh unknown
- 2006-11-02 AR ARP060104813A patent/AR058505A1/es not_active Application Discontinuation
- 2006-11-02 PE PE2006001343A patent/PE20071042A1/es not_active Application Discontinuation
- 2006-11-02 WO PCT/US2006/042914 patent/WO2007056117A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007056117A1 (en) | 2007-05-18 |
| US20070105887A1 (en) | 2007-05-10 |
| TW200803842A (en) | 2008-01-16 |
| AR058505A1 (es) | 2008-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071042A1 (es) | Producto farmaceutico que comprende temsirolimus y malato de sunitinib | |
| MX2024012963A (es) | Compuestos de modulacion de kras g12d | |
| CY1119176T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| CO6270257A2 (es) | Derivados de piridazinona | |
| GEP20125564B (en) | Pyrimidine derivatives as kinase inhibitors | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| CL2011001863A1 (es) | Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07). | |
| ECSP088598A (es) | Derivados de piridazinona | |
| EA201200578A1 (ru) | Сульфоксидные производные для лечения опухолей | |
| EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
| ECSP10010361A (es) | Derivados de piridazinona | |
| WO2010025872A3 (en) | Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl | |
| NZ622505A (en) | Therapeutic compounds and compositions | |
| AR059948A1 (es) | Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa | |
| TNSN08078A1 (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| EA200802007A1 (ru) | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
| CR11065A (es) | Administracion semanal de inhibidores de peptidasa de dipeptidilo | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| EA201100035A1 (ru) | Производные тиазолилпиперидина | |
| MX2009002842A (es) | Inhibidores heterociclicos de c-met y usos de los mismos. | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |